Literature DB >> 26501849

Evaluation of In-Use Stability of Anticoagulant Drug Products: Warfarin Sodium.

Agnes Nguyenpho1, Anthony B Ciavarella1, Akhtar Siddiqui1, Ziyaur Rahman1, Sohail Akhtar1, Robert Hunt1, Maxwell Korang-Yeboah1, Mansoor A Khan2.   

Abstract

The objective of the study was to evaluate the stability of warfarin products during use by patients or caregivers. For evaluation, three commercial products manufactured by different processes were selected and placed at 30°C/75%RH to simulate in use condition. Samples were withdrawn up to 12 weeks and analyzed for the physicochemical changes. Scanning electron microscopy demonstrated increasing holes and craters in the tablets over the timeframe. Near-infrared chemical imaging and powder X-ray powder diffraction corroborated the change arising from conversion of crystalline to amorphous forms of the drug. Hardness and disintegration time of the tablets were found to increase progressively. With increasing time, moisture contents of the products were found to increase and consequent decrease in isopropyl alcohol content of the product. Dissolution of the tablets in media at pH 4.5 demonstrated discrimination between crystalline and amorphous drug products. Overall, percent drug dissolved in each product at 30 min was found to decrease with increasing exposure time. Dissolution of drug decreased from 54% to 38% and 82% to 54% for the two products while the third product maintained consistently high level of dissolution. These results suggest that the drug product quality attributes can change during use.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  X-ray powder diffractometry; amorphous; clathrates; crystallinity; dissolution; near-infrared spectroscopy; stability

Mesh:

Substances:

Year:  2015        PMID: 26501849     DOI: 10.1002/jps.24657

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  1 in total

1.  Warfarin Sodium Stability in Oral Formulations.

Authors:  Evangelia Dimitrokalli; Stefani Fertaki; Michail Lykouras; Petros Kokkinos; Malvina Orkoula; Christos Kontoyannis
Journal:  Molecules       Date:  2021-11-01       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.